Regenerative medicine company Orthocell (ASX:OCC) has announced seven regulatory submissions are in progress or planned for its medical device platform products.
The submissions relate to Striate+ for guided bone and tissue regeneration and Remplir for peripheral nerve repair.
Striate+ has already been approved for use in Australia, Europe, the UK, and Canada. It is exclusively distributed globally by BioHorizons Implant Systems, one of the largest global dental implant companies. Orthocell is seeking approval of Striate+ Brazil and Singapore
Remplir is approved for sale in Australia and New Zealand. Device Technologies distribute it. Orthocell is seeking its approval in Singapore, the US, Canada, Thailand, Europe and the UK.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
